Skip to Main Content

Paper Details

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Lung Cancer
51
2014
Author NameAffiliation
Laszlo UrbanMatrahaza Healthcare Center and University Teaching Hospital
  • 1 - 1

Datasets

Release 1.2